Used primarily as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of selective kinase inhibitors. Its structure supports the construction of complex bioactive molecules, especially in oncology research. The tributylstannyl group enables cross-coupling reactions, facilitating the introduction of aromatic or heteroaromatic systems via palladium-catalyzed Stille coupling. This makes it valuable in medicinal chemistry for generating compound libraries aimed at targeting specific signaling pathways in cancer cells. Additionally, the difluoromethoxy and cyclobutyl moieties contribute to metabolic stability and improved binding affinity, enhancing the pharmacokinetic profile of resulting drug candidates.